[ET Net News Agency, 8 November 2021] Morgan Stanley lowered its target price for Sh
Pharma (02607) to HK$20.8 from HK$22 and maintained its "overweight" rating.
The research house said following 3Q results, it cuts 2021-2024 earnings estimates by
3-13% (lower sales and lower gross margins). Scenario values are down by 5-10%. (RC)